Enlivex Therapeutics (NASDAQ:ENLV) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Enlivex Therapeutics (NASDAQ:ENLV) from a hold rating to a sell rating in a report released on Saturday.

A number of other research firms also recently issued reports on ENLV. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. Zacks Research upgraded shares of Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $247.50.

Enlivex Therapeutics Stock Performance

NASDAQ:ENLV opened at $1.58 on Friday. The company has a market cap of $26.59 million, a PE ratio of -0.19 and a beta of 1.60. The company has a 50 day simple moving average of $5.90 and a two-hundred day simple moving average of $11.35. Enlivex Therapeutics has a 12 month low of $1.53 and a 12 month high of $27.15.

Hedge Funds Weigh In On Enlivex Therapeutics

Several institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its stake in Enlivex Therapeutics by 99.4% during the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock valued at $221,000 after acquiring an additional 156,336 shares during the period. HRT Financial LP raised its holdings in shares of Enlivex Therapeutics by 719.4% during the 4th quarter. HRT Financial LP now owns 153,990 shares of the company’s stock worth $108,000 after acquiring an additional 135,198 shares during the period. Bank of America Corp DE boosted its position in shares of Enlivex Therapeutics by 53.2% during the 1st quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock valued at $121,000 after acquiring an additional 45,303 shares during the last quarter. Jane Street Group LLC boosted its position in shares of Enlivex Therapeutics by 527.4% during the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after acquiring an additional 67,886 shares during the last quarter. Finally, XTX Topco Ltd grew its holdings in shares of Enlivex Therapeutics by 44.8% in the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock valued at $43,000 after purchasing an additional 19,132 shares during the period. Hedge funds and other institutional investors own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.